Why Amarin Shares Popped

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of cardiovascular-focused biopharmaceutical company Amarin (Nasdaq: AMRN  ) rallied as much as 19.5% today after a competitor released disappointing drug data.

So what: One company's pain is another company's gain, and we're seeing this in action today. Omthera Pharmaceuticals released late-stage study results on its omega3 drug, Epanova, last night and the data appear to show that it works less effectively than Amarin's AMR101. The data would put Epanova on par in effectiveness with GlaxoSmithKline's (NYSE: GSK  ) Lovaza, which is the only prescription-grade omega3 medication currently approved by the FDA.

Now what: The news appears to clear the way for AMR101 to potentially gain best-of-breed status in this drug class, if it can get approved. This also brings into question whether Amarin will be able to compete against Glaxo's significantly larger marketing budget. Ultimately, today's news is bullish for shareholders and the company deserves a spot on My Watchlist in the meantime because of this turn of events.

Craving more input? Start by adding Amarin to your free and personalized watchlist so you can keep up on the latest news with the company.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 26, 2012, at 2:31 PM, skm1965 wrote:

    You say Omthera Epanova is on par with Lovaza.

    Have you seen full results--they left out data on LDL.

    My guess is that it is worst than Lovaza.

    I asked Omthera as did Adam Feuerstein.

    No response.

    I think it is unethical to report data you like and exclude data you don't like.

    Why don't you contact dcarr@omthera.com and judge.Then write -whether it is better or worst than Lovaza.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1872351, ~/Articles/ArticleHandler.aspx, 11/26/2014 4:01:20 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement